Brachytherapy News and Research

RSS

Brachytherapy is a minimally invasive procedure that involves the use of radioactive seeds the size of rice grains. Brachytherapy, an out-patient procedure, usually takes 45 minutes to an hour to perform. Most patients can return to their normal activities within days. The success rates of prostate brachytherapy have compared favorably with success rates of radical prostatectomy and external beam radiation. In comparison studies, prostate brachytherapy has shown to have a favorable side effect profile when compared with other modalities. Clinical studies have shown that prostate brachytherapy has a cure rate of 94% for appropriately selected patients.

ASTRO leads the way to help physicians improve safety and reduce medical errors

The American Society for Radiation Oncology has committed to a six-point patient protection plan that will improve safety and quality and reduce the chances of medical errors, ASTRO Board Chairman Tim R. Williams, M.D., said today.

4 Feb 2010

IsoRay ships first set of Cesium-131 brachytherapy seeds to Canada

IsoRay, Inc. announced today that it has successfully shipped the first set of Cesium-131 brachytherapy seeds to a Canadian customer for the purpose of furthering research and development of Cesium-131 in Canada. Cesium-131 is currently approved by Health Canada for the treatment of low-risk prostate cancers and has been cleared by the US FDA for treatment of a wide variety of malignant disease (e.g. prostate, head and neck, brain, breast, lung, eye, etc.).

28 Jan 2010

IsoRay expands market awareness program by joining www.StockProfile.com

IsoRay, Inc., announced today that they have expanded their market awareness program by joining www.StockProfile.com, a customized web-based platform showcasing emerging growth stocks.

23 Jan 2010

World’s first Cs-131 implant for colorectal cancer performed at Weill Cornell Medical Center

IsoRay, Inc., announced today that on October 10, 2009, Dr. Bhupesh Parashar, Dr. A Gabriella Wernicke and Dr. KS Clifford Chao from the Department of Radiation Oncology, and Dr. Jeffery Milsom from the Department of Gastrointestinal Surgery, at Weill Cornell Medical Center performed the world’s first Cesium-131(Cs-131) implant for the treatment of colorectal cancer.

21 Jan 2010

Theragenics signs agreement with Core Oncology for distribution of TheraSeed palladium-103 brachytherapy seeds

Theragenics Corporation, a medical device company serving the surgical products and prostate cancer treatment markets, today announced that it has signed an agreement with Core Oncology, Inc. for the distribution of TheraSeed® palladium-103 brachytherapy seeds.

13 Jan 2010

Thames Valley Cancer Network implements ARIA system for Medical Oncology

A chemotherapy software solution that enables patients to become more involved in managing their own care has been successfully rolled out across a network of hospitals in the UK. The Thames Valley Cancer Network has implemented Aria for Medical Oncology™ from Varian Medical Systems and already has more than 850 clinical staff routinely using the system.

12 Jan 2010

Similar effectiveness in treatment options for low-risk prostate cancer; research may help improve patient outcomes

A comprehensive appraisal of the management and treatment options for low-risk prostate cancer found that the rates of survival and tumor recurrence are similar among the most common treatment approaches, although costs can vary considerably.

6 Jan 2010

ASTRO: Sexual function does not decline in prostate cancer patients receiving EBRT

Sexual function in prostate cancer patients receiving external beam radiation therapy (EBRT) decreases within the first two years after treatment but then stabilizes and does not continuously decline as was previously thought, according to a study in the January 1 issue of the International Journal of Radiation Oncology*Biology*Physics, the official journal of the American Society for Radiation Oncology (ASTRO).

6 Jan 2010

U.S. market for urological devices to reach over $5.4 billion in 2016

According to a new global report series by iData Research, the leading authority in medical device, dental and pharmaceutical market research, the U.S. market for urological devices is estimated to more than double in value by 2016, reaching over $5.4 billion.

6 Jan 2010

Four Latin American cancer patients receive treatment using RapidArc radiotherapy technology

Four cancer patients became the first in Latin America to receive treatment using a fast form of image-guided radiotherapy that potentially enables doctors to improve outcomes while extending modern care to more patients. Doctors at Hope International Centro de Radioterapia of Guatemala are now treating four patients using RapidArc® radiotherapy technology from Varian Medical Systems, one with recurring prostate cancer, one with a nasal cavity tumor, one with rectal cancer, and one with recurring glioblastoma multiforme--an aggressive type of brain tumor.

22 Dec 2009

Novalis Tx radiosurgery platform for modern radiotherapy and radiosurgery unveiled

Slovenian Minister of Health Borut Miklavcic today officially unveiled the nation's first Novalis Tx(TM) radiosurgery platform for modern radiotherapy and radiosurgery at the Oncology Institute of Ljubljana.

22 Dec 2009

Brachytherapy for lung cancer

A 58-year-old man who lives in Corona, Queens came to the emergency room of New York Hospital Queens (NYHQ) with extreme pain and tingling in his left arm. Although he did not realize it at the time, he had lung cancer. Recently, he made medical history as the first patient in the United States to be treated for lung cancer through the use of radioactive pellets placed directly in the tumor, and today his recovery is going well. Known as brachytherapy, this treatment approach is commonly used to treat prostate cancer.

18 Dec 2009

New statement on breast cancer by ACS underscores value of post-surgical radiation therapy

A new statement on breast cancer by the American College of Surgeons (ACS) underscores the value of an advanced approach to post-surgical radiation therapy provided by the Breast Clinic of Memphis.

18 Dec 2009

Varian Medical Systems introduces RapidArc radiotherapy technology in Finland

Cancer patients in Finland have gained access to more advanced treatments with the introduction of RapidArc® radiotherapy technology from Varian Medical Systems at the only private radiotherapy clinic in the Nordic region.

15 Dec 2009

New research highlights the benefit of shortened radiation course for patients with non-invasive breast cancer

New research being presented this week at the 32nd Annual CTRC-AACR San Antonio Breast Cancer Symposium by an investigator at The Cancer Institute of New Jersey (CINJ) highlights the benefit of a shortened radiation course to patients with the most common type of non-invasive breast cancer.

14 Dec 2009

SAVI applicator for breast brachytherapy can be an effective therapy for breast cancer

The SAVI™ applicator for breast brachytherapy is a safe, effective therapy for breast cancer, according to a newly published study in a peer-reviewed journal.

8 Dec 2009

Multi-Lumen MammoSite device to treat breast cancer now available at Jupiter Medical Center

Women fighting breast cancer after a lumpectomy have a new weapon in the battle, now available at Jupiter Medical Center's Foshay Cancer Center. Today, the hospital began treating patients with the Multi-Lumen MammoSite(R) device, just approved in September by the FDA.

4 Dec 2009

IsoRay to distribute Oncura's I-125 brachytherapy seed

IsoRay, Inc. announced today that it has signed a distribution agreement with Oncura to distribute the I-125 brachytherapy seed, OncoSeed™.

3 Dec 2009

RapidArc radiotherapy technology delivers highly-precise IMRT treatment

Former New Jersey Assemblyman Francis Bodine was surprised and delighted when his radiotherapy treatment sessions for prostate cancer went from about 20 minutes each day to less than five.

2 Dec 2009

Varian Medical Systems' RapidArc radiotherapy enables faster stereotactic treatment of lung tumors

Researchers from VU University Medical Center in Amsterdam have reported that RapidArc® radiotherapy from Varian Medical Systems has clinical advantages over earlier fixed-beam approaches to stereotactic treatments of lung tumors. Their findings, based on treatment of 85 medically inoperable lung cancer patients, were reported at the recent annual meeting of the American Society for Radiation Oncology (ASTRO) in Chicago and a condensed version has been published in the 'Green Journal' (Radiotherapy and Oncology) 93 (2009).

1 Dec 2009

Brachytherapy News and Research

Further Reading

ASTRO leads the way to help physicians improve safety and reduce medical errors

IsoRay ships first set of Cesium-131 brachytherapy seeds to Canada

IsoRay expands market awareness program by joining www.StockProfile.com

World’s first Cs-131 implant for colorectal cancer performed at Weill Cornell Medical Center

Theragenics signs agreement with Core Oncology for distribution of TheraSeed palladium-103 brachytherapy seeds

Thames Valley Cancer Network implements ARIA system for Medical Oncology

Similar effectiveness in treatment options for low-risk prostate cancer; research may help improve patient outcomes

ASTRO: Sexual function does not decline in prostate cancer patients receiving EBRT

U.S. market for urological devices to reach over $5.4 billion in 2016

Four Latin American cancer patients receive treatment using RapidArc radiotherapy technology

Novalis Tx radiosurgery platform for modern radiotherapy and radiosurgery unveiled

Brachytherapy for lung cancer

New statement on breast cancer by ACS underscores value of post-surgical radiation therapy

Varian Medical Systems introduces RapidArc radiotherapy technology in Finland

New research highlights the benefit of shortened radiation course for patients with non-invasive breast cancer

SAVI applicator for breast brachytherapy can be an effective therapy for breast cancer

Multi-Lumen MammoSite device to treat breast cancer now available at Jupiter Medical Center

IsoRay to distribute Oncura's I-125 brachytherapy seed

RapidArc radiotherapy technology delivers highly-precise IMRT treatment

Varian Medical Systems' RapidArc radiotherapy enables faster stereotactic treatment of lung tumors

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News